Interferes with the first step of folic acid synthesis. When used in combination with trimethoprim, it can double block the folic acid metabolism of bacteria, enhance the synergistic antibacterial effect, and reduce drug-resistant strains.

Selectively inhibits the action of dihydrofolate reductase. When used in combination with sulfamethoxazole, it can double-block the bacterial folate metabolism, enhance the synergistic antibacterial effect, and reduce drug-resistant strains.

It participates in amino acid metabolism, synthesis of neurotransmitters, synthesis of collagen and tissue cell interstitial, can reduce the permeability of capillaries, accelerate blood coagulation, stimulate coagulation function, promote iron absorption in the intestine, promote the decrease of blood lipids, increase resistance to infection, participate in detoxification function, and has antihistamine effect and prevents the formation of carcinogens (nitrosamines).

Participate in cell energy metabolism and protein synthesis in the body, increase the activity of related metabolic enzymes, improve liver function, and promote the recovery of damaged liver

This product is a macrolide antibiotic, which has an inhibitory effect on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Peptostreptococcus, and Propionibacterium acnes. In addition, it also has an inhibitory effect on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. The mechanism of action of this product is to inhibit the association of the 50S subunit of the nuclear protein and inhibit protein synthesis to produce an antibacterial effect.

This product is a macrolide antibiotic, which has inhibitory effects on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Streptococcus peptostreptococcus, and Propionibacterium acnes. In addition, it also has inhibitory effects on mycoplasma. The characteristics of this product are that its antibacterial activity in vitro is similar to that of erythromycin, but its antibacterial activity in vivo against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. There is cross-resistance between this product and erythromycin. The mechanism of action of this product is to inhibit the association of the 50S subunit of the nuclear protein and inhibit protein synthesis to produce an antibacterial effect.